| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT00662220 2007-005344-25 Details | 2014-07-14 Interventional | 3 | 110 | Interferon-alph… Peginterferon a… Ribavirin Hepatitis Hepatitis A Hepatitis C Hepatitis C, Ch… Hepatitis, Chro… Chronic Hepatit… | Due to the arrival of DAAs replacing standard of care for genotype 1 patients the VIRID study
had to be terminated. - | |||
| NCT01505881 2011-002285-21 Details | 2014-07-11 Interventional | 2 | 158 | Dabigatran Warfarin Thromboembolism Heart Valve Pro… | - This study was terminated prematurely due to safety concerns arising during conduct of the trial. | |||
| NCT01043601 Details | 2014-07-11 Interventional | 2 | 0 | Formoterol Fuma… COPD | Similar data obtained in another study [see NCT01085045], therefore study not implemented. - | |||
| NCT02184260 Details | 2014-07-10 Interventional | 4 | 58 | Dipyrone Ischemic Stroke Stroke | - - | |||
| NCT02183246 Details | 2014-07-08 Interventional | 3 | 3 | Porfiromycin Head and Neck N… | - - | |||
| NCT02182700 Details | 2014-07-08 Interventional | 3 | 47 | Albuterol Bromides Ipratropium Asthma | - - | |||
| NCT01603394 Details | 2014-07-08 Interventional | 4 | 9 | Pregabalin Neuralgia Neuralgia, Post… Postherpetic Ne… | See termination reason in detailed description. Outcome measure PCS was removed in protocol amendment1. Study stopped due to low enrolment and not safety. Efficacy analyses were not performed; safety results are described. Overall risk-benefit of pregabalin has not changed due to trial termination | |||
| NCT01187615 Details | 2014-07-08 Interventional | 1 | 9 | Cisplatin Pemetrexed Carcinoma, Non-… Lung Neoplasms Small Cell Lung… | - - | |||
| NCT00890097 Details | 2014-07-03 Interventional | 3 | 772 | Ophthalmic Solu… Atrophy Geographic Atro… Macular Degener… Age-Related Mac… | Treatment ineffective - | |||
| NCT01145404 Details | 2014-07-02 Interventional | 2 | - | Capecitabine Lapatinib Esophageal Neop… GastroEsophagea… | Changes of SoC for third line therapy resulting in poor recruitment - | |||
| NCT00002948 Details | 2014-07-02 Interventional | 1 | - | Topotecan Unspecified Adu… | - - | |||
| NCT00608231 Details | 2014-07-01 Interventional | 2/3 | 0 | Dexmedetomidine Dystonia Essential Tremo… Parkinson Disea… Parkinson's Dis… | Intraoperative recording could not be maintained for required period - | |||
| NCT00440271 2005-005264-86 Details | 2014-06-27 Interventional | 3 | 33 | Enfuvirtide Maraviroc Raltegravir Pot… Reverse Transcr… Ritonavir Tipranavir HIV Infections | - The study was terminated early due to low patient enrollment, and, therefore, no analysis was performed on the primary and secondary endpoints | |||
| NCT00165828 2005-000260-57 Details | 2014-06-27 Interventional | 4 | 157 | Zonisamide Epilepsy Seizures | - - | |||
| NCT01890408 Details | 2014-06-26 Interventional | 2 | 5 | Ropivacaine Hepatic Resecti… Laparotomy | promoter decision - | |||
| NCT00975299 2008-007460-42 Details | 2014-06-26 Interventional | 1 | 16 | Bombesin Prostatic Neopl… Diagnostic Imag… | - - | |||
| NCT00076401 Details | 2014-06-26 Interventional | 2 | - | Motexafin gadol… Leukemia Leukemia, Lymph… Leukemia, Lymph… Leukemia, Lymph… | - - | |||
| NCT02092961 Details | 2014-06-25 Interventional | 2 | 198 | Adalimumab Arthritis Arthritis, Rheu… Rheumatoid Arth… | AZ decision to discontinue fostamatinib development in RA; rights to fostamatinib returned to
Rigel Pharmaceuticals. - | |||
| NCT02172508 Details | 2014-06-24 Interventional | 4 | 15 | Tiotropium Brom… Dyspnea Lung Diseases Lung Diseases, … Pulmonary Disea… | - - | |||
| NCT02172131 Details | 2014-06-24 Interventional | 1 | 64 | Olodaterol Healthy | - - |